Core Insights - The China International Import Expo (CIIE) serves as a significant platform for enhancing Swiss-Chinese economic and trade cooperation, acting as a "multiplier" for Swiss companies to expand in the Chinese market [1][3] - The Swiss Center has evolved into a key navigator for Swiss enterprises entering the Chinese market, helping over 100 companies participate in CIIE since its inception [2][3] Group 1: Swiss Center's Role - The Swiss Center has been a consistent participant in CIIE, helping Swiss companies, especially SMEs, showcase products and find business partners [2] - The Center has witnessed a growing recognition and satisfaction among Swiss enterprises regarding CIIE, with participation expanding from four companies in the first year to 24 companies in the seventh year [8][11] Group 2: Innovations and Developments - The Swiss Center has introduced a Business Development department to specifically support Swiss consumer goods companies, reflecting the increasing number of exhibitors at CIIE [6] - A new position, "Customer Success Manager," was created to assist Swiss companies in successfully entering the Chinese market, with a focus on reducing the product entry cycle from 12 months to 3 months [6][7] Group 3: Market Opportunities - CIIE provides Swiss brands with opportunities to test products, expand sales channels, and enter the Chinese market, leading to high participation enthusiasm among Swiss enterprises [11] - The introduction of an innovation incubation area at CIIE aims to meet the needs of Swiss startups looking to enter the Chinese market, showcasing 14 medical technology companies [11]

Core Viewpoint - Smith+Nephew has announced a strategic partnership with Standard Health to develop the first Orthopaedic Ambulatory Surgery Centre in the UK, aimed at improving access to advanced joint repair and replacement technologies for patients [1][2]. Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with annual sales of $5.8 billion in 2024 [9]. - Standard Health specializes in orthopaedic care and has provided NHS services since 2012, with plans for nationwide expansion [10]. Partnership Details - The new centre in Poole, Dorset, will cater to both NHS and private patients, offering procedures such as rotator cuff repair and knee replacements, and is expected to open in 2025 [1][3]. - Standard Health plans to open an additional 10 sites in the UK over the next three years, totaling 20 by 2030 [2]. Operational Model - The centre will adopt the Ambulatory Surgery Center (ASC) model from the US, which has proven benefits including increased procedural efficiency and high patient satisfaction rates [3][6]. - In the US, ASCs account for over 50% of all outpatient surgical procedures, with more than 6,000 facilities currently operating [3]. Market Demand - There are over 850,000 individuals waiting for orthopaedic surgery in the UK, highlighting the need for independent providers to meet this demand [3]. - The partnership aims to address the long wait times for procedures in the UK, providing a sustainable model for care [4]. Expected Benefits - The ASC model is associated with a 92% patient satisfaction rate and can reduce costs of joint replacements by 40% compared to hospital-based surgeries [6]. - The collaboration is expected to enhance the quality of care for patients and provide value for NHS commissioners [4].

Core Viewpoint - Brainlab AG, a medical technology company, has announced plans for an IPO on the Frankfurt Stock Exchange, aiming to raise up to €200 million to fund growth initiatives and strengthen its balance sheet and sales team [1] Company Summary - Brainlab is headquartered in Munich and focuses on developing software that enhances the precision, data-driven approach, and minimally invasive nature of surgical and cancer treatments [1] - The company also provides tools to help hospitals plan and guide medical procedures [1] Financial Summary - The IPO is expected to include secondary shares, although the announcement did not specify the number of shares to be issued [1] - The raised capital will be allocated towards growth plans, reinforcing the company's financial position and expanding its sales capabilities [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 自願公告 質子治療大模型正式發佈 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 本公司於腫瘤精準診療技術領域取得重要進展，本公司自主研發的質子治療垂直 領域大語言模型正式發佈，並成功部署於廣州泰和腫瘤醫院。自廣州泰和腫瘤醫 院質子治療開診以來，質子治療已完成多例高質量患者治療案例，展現出了治療 精準、療效顯著、副作用降低等突出優勢。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 中國北京，2025年5月27日 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事 ...

Core Viewpoint - The article emphasizes "unconventional" entrepreneurial thinking as a means to identify and seize opportunities for success, suggesting that mindset plays a crucial role in responding to impending changes [2]. Group 1: "We Can Do It" - Companies should focus on their core competencies and be open to exploring new opportunities beyond their traditional capabilities, as demonstrated by Brazilian entrepreneur Arnold Correia, who successfully ventured into satellite broadcasting despite lacking prior knowledge [3][4]. Group 2: "Problem-Oriented, Not Product-Oriented" - Entrepreneurs should prioritize solving problems rather than merely focusing on product innovation. Jonathan Thorne's development of a non-stick surgical tweezer illustrates the importance of addressing significant issues in specific medical fields rather than just enhancing existing products [5][6]. Group 3: "Focus on Specific Markets" - Identifying and addressing needs within niche markets can lead to substantial opportunities. Phil Knight and Bill Bowerman's creation of Nike stemmed from recognizing the unique requirements of long-distance runners, leading to the development of specialized running shoes [7]. Group 4: "Boldly Ask for Money" - For startups, securing cash flow is vital. Elon Musk's approach at Tesla, where he sold 100 Roadsters before production, exemplifies the effectiveness of pre-selling to generate capital for development [8][9]. Group 5: "Borrowing Resources" - Entrepreneurs can leverage existing resources to minimize initial investment. Tristram and Rebecca Mayhew's Go Ape company successfully partnered with the Forestry Commission to utilize their parks for adventure courses, demonstrating the potential of collaborative resource sharing [10].

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 近日，美国医疗技术公司 ClearPoint Neuro （纳斯达克股票代码： CLPT ） 宣布与 Oberland Capital 达成一项融资协议， 总额高达 1.1 亿美元 （约合 8亿人民币）， 用于支持其在精准神经导航和药物传递领域的技术开发和商业化。该笔融资包括 1.05 亿美元的结构性债务融资以及 350 万美元的注册股权 投资。 该笔融资旨在强化公司在 手术导航、细胞 / 基因治疗辅助技术以及全球市场布局方面 的战略执行力，进一步扩大其作为 " 介入式神经科学平台 " 的行业角 # 融 资 细节 此次融资由 Oberland Capital 独家提供，是一项结合债务与股权的结构化融资安排，总金额最高达 1.1 亿美元 。 首期融资总额为 3350 万美元 ， 已于交易完成时到账：其中 3000 万美元为初始债务融资；350 万美元为普通股投资，按协议签署前 3 ...

Core Viewpoint - The article discusses the development of wearable near-infrared (NIR) upconversion contact lenses (UCL) that enable humans to perceive NIR images, expanding the visual spectrum beyond the visible light range [3][9]. Group 1: Research Development - A research team from multiple institutions developed UCL that possess suitable optical properties, hydrophilicity, flexibility, and biocompatibility, allowing for the perception of NIR spatial and temporal color images [3][5]. - The UCL achieved a high doping ratio (7-9%) of upconversion nanoparticles (UCNP) while maintaining over 90% transparency in the visible light spectrum, significantly outperforming previously reported materials [5][6]. Group 2: Functional Capabilities - Mice wearing UCL were able to perceive NIR light and distinguish different temporal frequencies and orientations of NIR information [6]. - Human volunteers wearing UCL could see a range of NIR light intensities and accurately identify time-encoded information [6][9]. Group 3: Technological Innovations - The research team developed a wearable eyeglass system integrated with UCL to enhance spatial resolution, allowing volunteers to recognize complex NIR patterns with clarity similar to visible light vision [6][9]. - The use of trichromatic UCNP in the UCL enables the conversion of three different NIR wavelengths into red, green, and blue visible light, facilitating the perception of multi-spectral NIR colors [7][9]. Group 4: Future Applications - This technology has potential applications in medical fields, information processing, and visual assistance technologies, and may offer new solutions for treating visual disorders such as color blindness [9][12]. - The research emphasizes the need for further optimization, including improving upconversion efficiency and achieving directional emission of light from the lenses [12].

Assertio Holdings (ASRT) Conference Summary Company Overview - Assertio Holdings is a specialty pharmaceuticals company with a market cap of approximately $70 million and shares trading at around 70¢ [2][4] - The company is focused on long-term growth and has a leadership team with extensive commercial experience in various therapeutic areas [5][6] Core Assets and Financial Performance - Assertio's core assets include Rovidone and SYMPAZAN, with Rovidone being a novel long-acting G-CSF approved in the last twenty years, targeting a market worth about $1 billion [8][9] - The company reported net sales of $26 million for the first quarter and maintains a positive adjusted EBITDA with a cash balance of nearly $90 million [9] - The financial outlook for the year includes projected net sales of $108 to $123 million and non-GAAP EBITDA of $10 to $20 million [10] Transformation and Growth Strategy - The company is in a transformation phase, simplifying its corporate structure and optimizing its asset portfolio, focusing on growth assets like Rovidone and SYMPAZAN [12][15] - Assertio aims to reduce legal exposure, which will allow for reinvestment into the business and positively impact EBITDA [13][14] - Business development is seen as a key enabler for future growth, with a focus on oncology, neurology, and rare diseases [14] Product Insights - Rovidone contributes over half of the total net sales and is expected to grow modestly this year, with plans to expand into the commercial segment by 2026 [19][21] - SYMPAZAN, an oral film formulation for Lennox Gastaut syndrome, is projected to grow to $13 million this year and has the potential to reach $25 million in the coming years [28] Competitive Landscape - The market for white blood cell stimulants is competitive, with Rovidone competing against biosimilars like Neulasta. Assertio is focused on managing average selling prices (ASP) smartly to sustain growth [23][24] Legal and Operational Improvements - Assertio has successfully reduced its litigation overhead, particularly related to opioid litigation, which has allowed for a cleaner balance sheet and operational focus [36][38] - The company has divested certain assets to streamline operations and eliminate legal distractions [38] Future Outlook - The CEO expressed optimism about the company's trajectory, aiming for significant growth and improved operational efficiency over the next year [41][42] - Assertio is positioned to explore mergers and acquisitions to enhance its portfolio, supported by a strong balance sheet with $40 million in convertible debt due in 2027 [34][35] Key Takeaways - Assertio is undergoing a transformation aimed at growth, with a focus on optimizing its asset portfolio and reducing legal distractions [12][15] - The company has a solid financial outlook and is strategically positioned to capitalize on growth opportunities in specialty pharmaceuticals [10][14] - Assertio's leadership is optimistic about future performance, with plans to enhance product offerings and expand market presence [41][42]

Group 1 - JD Health and BD Medical have launched a new service called "Caring for Bedridden Women's Health: Professional Care Delivered to Home," starting in Beijing [2][3] - The service combines instant retail of medical health products with at-home nursing services, providing a new solution for urinary management for bedridden female patients [2][3] - The target demographic includes women with urinary incontinence, limited mobility, and post-operative patients, addressing complications associated with catheter use [2] Group 2 - PureWick® is an innovative non-invasive urinary management solution designed specifically for bedridden women, improving comfort and dignity while simplifying the workflow for caregivers [3] - Users in Beijing can order PureWick® products through the JD app and receive at-home care services from experienced nurses, ensuring professional care and privacy [3] - This collaboration aims to contribute to the "Healthy China 2030" strategic goals by providing more efficient and user-centered home care solutions [4]

一句话趋势：机器人与半导体投资热度高涨，低空经济成科技与制造赛道热门。 过去一周披露的投融资案例显示，科技与制造依然是市场关注的重点，新资金持续向前沿技术集聚，涵 盖机器人、半导体、低空经济、先进制造等领域，呈现出资本对科技创新和产业升级的支持以及对未来 科技趋势的布局。 在已披露交易中： 21创投不完全统计，5月12日—5月18日，报告日期内国内一级市场发生融资事件37起。其中，有32笔融 资披露了融资金额和币种信息，总规模约合人民币42.65亿元。 01、机器人、半导体和医疗技术领域完成多笔融资 本周融资数量最多的行业领域仍是科技与制造。在三大行业领域的诸多赛道中，机器人赛道完成8笔融 资，融资金额超13.4亿元人民币；半导体赛道完成5笔融资，融资金额超7.75亿元人民币；医疗技术赛道 完成4笔融资，披露的融资金额超1亿元人民币。 02、北京市、广东省和上海市完成多笔融资 从披露获投企业的地域分布来看，本周的融资地区主要集中在北京市、广东省和上海市，分别完成8 笔、8笔、6笔融资。 03、哪些投资机构较为活跃 从机构投资活跃度来看，本周珠海科创投、中科创星、毅达资本、水木清华校友种子基金、深创投和临 港数 ...